Vascular endothelial growth factor (VeGf) and placental growth factor (plGf) plays a crucial role in breakdown of the blood-retinal barrier due to hyperpermeability in diabetic retinopathy (DR). However, the distinct signaling driven by VeGf and plGf in the pathogenesis of DR remains unclear. in this study, we investigated VeGf-and plGf-related signaling pathways and their roles in cultured human microvascular retinal endothelial cells (hRECs) under high glucose conditions (HG; 25 mM). Apoptotic cell death was evaluated, and fitc conjugated bovine serum albumin across monolayer hRecs served as an index of permeability. Western blots were used to assess the protein levels of VeGf and PlGF, as well as the phosphorylation of p38MAPK, STAT1 and Erk1/2. Knockdown of VEGF and PlGF was performed by using siRNA. Following HG treatment, increases of VEGF and PlGF as well as PKC activity were detected in hRECs. Increased phosphorylations of p38MAPK Thr180/Thr182 , STAT1 Ser727 , and Erk1/2 Tyr202/Tyr185 as well as VEGFR1 Tyr1213 and VEGFR2 Tyr1175 were also detected in HG-treated hRecs. Inhibition of PKC activity by Go 6976 prevented HG-induced increases of phosphor-Erk1/2 and nitric oxide synthase (NOS1) expressions as well as hyperpermeability, whereas inhibition of p38MAPK pathway by SB203580 selectively suppressed activation of STAT1 and decreased apoptotic cell death under HG conditions. Moreover, VEGF knockdown predominantly inhibited activation of VEGFR2, and phosphorylation of p38MAPK and STAT1, as well as apoptotic cell death in HG-treated hRECs. Nevertheless, PlGF knockdown mainly suppressed phosphorylation of VEGFR1, PKC, and Erk1/2, as well as NOS1 expressions and hyperpermeability. Taken together, we provide evidence demonstrating that HG-induced elevation of plGf is responsible for hyperpermeability mainly through increasing activation of PKC-Erk1/2-NOS axis via VEGFR1, while HG-induced elevation of VEGF is associated with induction of apoptotic cell death mainly through increasing activation of p38MAPK/STAT1 signaling via VEGFR2.Diabetic retinopathy (DR), one of the most prominent microvascular complications of diabetes mellitus, is the leading cause of new-onset blindness in the developed countries 1,2 . It was reported that across China, the prevalence of DR and sight-threatening DR was 27.9% and 12.6% in diabetes, respectively 3 .
Our findings will facilitate the understanding of the mechanism involved in ZnO nanoparticle-induced cytotoxicity in murine photoreceptor cells via potassium channel block and Na /K -ATPase inhibition.
The present study investigated the function of microRNA (miR)-106b in the proliferation, migration and invasion of retinoblastoma (RB) cells, and aimed to elucidate the underlying mechanism. A total of 56 patients with RB were enrolled in the present study. The expression of miR-106b in RB tissues was measured by reverse transcription quantitative polymerase chain reaction. After transfection with miR-106b mimics or miR-106b inhibitor, a Cell-Counting kit-8 assay was used to determine the proliferation of WERI-Rb-1 cells and a Transwell assay was employed to measure the migration and invasion of the cells. Western blot analysis was performed to determine the expression of zinc finger and BTB domain containing 4 (ZBTB4) protein. By silencing or overexpression of ZBTB4 protein, the biological functions of ZBTB4 in WERI-Rb-1 cells were studied. A dual luciferase reporter assay was performed to test whether ZBTB4 was a target gene of miR-106b. The expression of miR-106b in RB tissues was elevated and closely associated with the severity of the disease. Overexpression of miR-106b increased but inhibition of miR-106b expression decreased the proliferation, migration and invasion abilities of WERI-Rb-1 cells. In addition, overexpression of miR-106b decreased but inhibition of miR-106b expression increased ZBTB4 protein expression in WERI-Rb-1 cells. Similarly, overexpression of ZBTB4 reduced but inhibition of ZBTB4 expression promoted the proliferation, migration and invasion of WERI-Rb-1 cells. Finally, miR-106b regulated the expression of ZBTB4 by binding to the 3′-untranslated region of the ZBTB4 gene. The present study demonstrated that increased expression of miR-106b in RB tissues is positively associated with the metastasis and differentiation of RB cells. As an oncogene, miR-106b promotes the proliferation, migration and invasion of WERI-Rb-1 cells by inhibiting the expression of ZBTB4 protein.
Purpose: This study was designed to explore the application of femtosecond laser-assisted deep anterior lamellar keratoplasty (DALK) in the management of keratoconus. Methods: A total of 7 patients with keratoconus underwent femtosecond laser-assisted DALK. Femtosecond laser was performed to create corneal cuts on both donor and recipient. Average thinnest corneal thickness was measured with B-mode ultrasound and visual acuity was evaluated by logarithm visual chart. The follow-up endured for (8.9 ± 2.3) months on average, ranging from 12 to 50 months. Results: Corneal pachymetry was measured as (382 ± 44) m, ranging from 381 to 462 m. Mean uncorrected visual acuity (UCVA) was (0.06 ± 0.06) prior to surgery, ranging from 0.01 to 0.15 and mean preoperative best corrected visual acuity (BCVA) was 0.41 ± 0.35 (range: 0.12-1.00). Donor corneal lamellar diameter was measured as 0.22 mm larger compared with that of the recipient. Mean donor corneal lamellar diameter was (7.7 ± 0.3) mm and mean corneal thickness was (371 ± 38) m. A clear graft was noted in all cases after the surgery. Mean corneal thickness was (457 ± 33) m. During final follow-up, mean UCVA was significantly improved to (0.31 ± 0.15) and (0.59 ± 0.23) for mean BCVA. Conclusions: Femtosecond laser-assisted DALK is an efficient and safe treatment of keratoconus.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.